enoximone has been researched along with Pulmonary Hypertension in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huth, R; Michel-Behnke, I; Schranz, D; Wippermann, CF | 1 |
| Butt, AY; Clelland, CA; Cremona, G; Dinh-Xuan, AT; Higenbottam, TW; Pepke-Zaba, J | 1 |
| Brüssel, T; Hachenberg, T; Hammel, D; Holst, D; Möllhoff, T | 1 |
| Bauer, J; Dapper, F; Demirakça, S; Hagel, KJ; Knothe, C; Thul, J | 1 |
| Mitrovic, V; Schönburg, M; Schulz, O; Thormann, J | 1 |
| Besse, B; Coulaud, JM; Faitg, R; Lissac, J; Poler, F; Rezgui, N | 1 |
| Leeman, M; Lejeune, P; Melot, C; Naeije, R | 1 |
2 trial(s) available for enoximone and Pulmonary Hypertension
| Article | Year |
|---|---|
Cardiopulmonary effects of enoximone or dobutamine and nitroglycerin on mitral valve regurgitation and pulmonary venous hypertension.
Topics: Adrenergic beta-Agonists; Adult; Aged; Blood Pressure; Cardiac Output; Cardiopulmonary Bypass; Cardiotonic Agents; Dobutamine; Drug Combinations; Elective Surgical Procedures; Enoximone; Follow-Up Studies; Heart; Heart Rate; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Lung; Middle Aged; Mitral Valve Insufficiency; Nitroglycerin; Oxygen; Phosphodiesterase Inhibitors; Prospective Studies; Pulmonary Artery; Pulmonary Gas Exchange; Vascular Resistance; Vasodilator Agents | 1997 |
[Hemodynamic effects of enoximone and comparison with dobutamine in patients with chronic respiratory insufficiency and pulmonary arterial hypertension].
Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Dobutamine; Enoximone; Female; Heart Ventricles; Humans; Hypertension, Pulmonary; Imidazoles; Lung Diseases, Obstructive; Male; Middle Aged; Pulmonary Circulation; Respiratory Insufficiency; Vasodilation | 1990 |
5 other study(ies) available for enoximone and Pulmonary Hypertension
| Article | Year |
|---|---|
Norepinephrine, enoximone, and nitric oxide for treatment of myocardial stunning and pulmonary hypertension in a newborn with diaphragmatic hernia.
Topics: Enoximone; Hernia, Diaphragmatic; Humans; Hypertension, Pulmonary; Infant, Newborn; Male; Myocardial Stunning; Nitric Oxide; Norepinephrine; Treatment Outcome | 1995 |
In vitro pulmonary vasorelaxant effect of the phosphodiesterase inhibitor enoximone.
Topics: Animals; Dose-Response Relationship, Drug; Endothelium, Vascular; Enoximone; Hypertension, Pulmonary; In Vitro Techniques; Nitric Oxide; Pulmonary Artery; Swine; Vasodilator Agents | 1993 |
Perioperative management of pulmonary hypertension after heart transplantation in childhood.
Topics: Alkalies; Alprostadil; Cardiac Output, Low; Cardiopulmonary Bypass; Cardiotonic Agents; Cause of Death; Child; Child, Preschool; Cold Temperature; Dobutamine; Enoximone; Extracorporeal Circulation; Graft Rejection; Heart Transplantation; Humans; Hypertension, Pulmonary; Infant; Intraoperative Care; Opportunistic Infections; Phosphodiesterase Inhibitors; Postoperative Complications; Pulmonary Artery; Survival Rate; Time Factors; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Right | 1997 |
High-dose enoximone to evaluate reversibility of pulmonary hypertension: is there a diagnostic value of neurohormonal measurements?
Topics: Angiotensin II; Atrial Natriuretic Factor; Biomarkers; Cardiac Catheterization; Catecholamines; Endothelin-1; Enoximone; Female; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Middle Aged; Peptidyl-Dipeptidase A; Phosphodiesterase Inhibitors; Prognosis; Pulmonary Artery; Pulmonary Veins; Severity of Illness Index | 1999 |
Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPD.
Topics: Aged; Airway Resistance; Blood Pressure; Bronchodilator Agents; Cardiac Output; Enoximone; Female; Heart Rate; Humans; Hypertension, Pulmonary; Imidazoles; Infusions, Intravenous; Lung Compliance; Lung Diseases, Obstructive; Male; Middle Aged; Pulmonary Wedge Pressure; Vascular Resistance; Vasodilator Agents | 1987 |